Beijing's Brii Bio reported data from a global Phase III trial that showed its combination mAb COVID-19 therapy was equally effective in patients who received the therapy in days 1-5 after onset of symptoms as those in days 6-10. The company said the data suggest the combination therapy will be effective among patients in later stages of their disease. Overall, Brii reported the candidate, which consists of two non-competing SARS-CoV-2 mAbs derived from convalesced COVID-19 patients, reduced hospitalizations and death by 78% among high-risk patients. More details.... Stock Symbol: (HK: 2137) Share this with colleagues: // //